SYD985

trastuzumab duocarmazine · Byondis B.V.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for SYD985, covering 2023-10-19 to 2024-05-30. Get the full timeline:

Most recent: Clinical Trial Update: SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma [Phase 2]